Related by context. All words. (Click for frequent words.) 79 pharmacokinetics PK 79 pharmacodynamic profile 77 safety tolerability pharmacokinetics 75 pharmacodynamic effects 74 safety tolerability pharmacodynamics 72 pharmacodynamics PD 72 tolerability pharmacokinetics 72 pharmacodynamic PD 72 limiting toxicity DLT 71 pharmacodynamic properties 71 pharmacodynamics 71 safety tolerability 71 pharmacodynamic markers 71 pharmacokinetics pharmacodynamics 70 pharmacokinetic parameters 70 pharmacokinetic PK 69 pharmacokinetics 69 oral prodrug 69 Maximum Tolerated Dose MTD 68 ascending doses 68 pharmacokinetic profile 68 pharmacodynamic profiles 68 multicenter Phase II 67 pharmacodynamic 67 HGS ETR2 67 preclinically 67 ritonavir boosted 67 tolerated dose MTD 67 pomalidomide 67 Phase Ib clinical trials 67 varespladib 67 phase Ib 67 blinded randomized placebo controlled 67 PXD# 67 preclinical efficacy 66 antiviral efficacy 66 selective modulator 66 dose escalation trial 66 analgesic efficacy 66 Pharmacokinetic 66 ENMD # 66 galiximab 66 SCH # 66 neratinib 66 viral kinetic 66 nab paclitaxel 66 urate lowering 66 Phase 1b trial 66 pharmacokinetic 66 Carfilzomib 66 ZYBRESTAT fosbretabulin 66 ganetespib 66 ascending dose 65 placebo controlled dose escalation 65 tolerability 65 pharmacokinetic characteristics 65 JAK inhibitor 65 fosbretabulin 65 dose escalation study 65 anti leukemic 65 plasma pharmacokinetics 65 anticancer activity 65 MAGE A3 ASCI 65 investigational humanized monoclonal antibody 65 pharmacokinetic pharmacodynamic 65 Phase Ib clinical 65 novel VDA molecule 65 efficacy tolerability 65 NEUGENE antisense 65 antiviral activity 65 favorable pharmacokinetic profile 64 S/GSK# 64 solithromycin 64 PRTX 64 virus HCV protease inhibitor 64 orally bioavailable 64 randomized multicenter trial 64 multicenter Phase III 64 ON #.Na 64 investigational hepatitis C 64 riociguat 64 alvespimycin 64 Afatinib 64 teriflunomide 64 pharmacokinetic profiles 64 dose proportionality 64 Tyrima 64 Enzastaurin 64 GLYX 64 relapsed MM 64 immunogenicity 64 immunological responses 64 CBLC# 64 Cloretazine 64 dose dose escalation 64 #I TM# 64 antitumor activity 63 MGd 63 maximally tolerated dose 63 CR# vcMMAE 63 axitinib 63 tipifarnib 63 PEG SN# 63 GMX# 63 sulodexide 63 mertansine 63 RSD# oral 63 NP2 Enkephalin 63 evaluating tivozanib 63 reactogenicity 63 orally administered inhibitor 63 HCD# [002] 63 Phase Ib study 63 biodistribution 63 mapatumumab 63 phase IIa clinical 63 rNAPc2 63 davunetide intranasal AL 63 viral kinetics 63 PSN# [002] 63 multicenter randomized placebo controlled 63 investigational protease inhibitor 63 favorable tolerability 63 histone deacetylase inhibitor 63 Tarceva TM 63 ongoing Phase 1b 63 IAP inhibitor 63 Pharmacokinetic PK 63 oral Janus kinase 63 velafermin belinostat 63 Phase Ia 63 double blinded randomized 63 PDX pralatrexate 63 NOX E# 63 TRO# 63 placebo controlled randomized 63 OMP #M# 63 oral antiviral 63 TO AVOID PREGNANCY WHILE 63 erlotinib Tarceva ® 62 Pharmacokinetics PK 62 oral rivaroxaban 62 trodusquemine 62 CANCIDAS 62 subcutaneous formulation 62 pharmacokinetic PK profile 62 liposomal formulation 62 thorough QT 62 phase IIb study 62 AEG# 62 oral deforolimus 62 velafermin 62 subcutaneous SC 62 pan HDAC inhibitor 62 Teriflunomide 62 randomized Phase III 62 LUX Lung 62 Azedra 62 CK # administered 62 CG# [003] 62 indibulin 62 PRT# 62 systemically administered 62 masked placebo controlled 62 multicentre randomized 62 TPI ASM8 62 vidofludimus 62 dose escalation Phase 62 cariprazine 62 DAVANAT 62 anti amnesic 62 Kahalalide F 62 stated Michelle Berrey 62 TG# [003] 62 RG# ITMN 62 busulfan 62 pharmacokinetic PK study 62 prospective randomized controlled 62 single ascending dose 62 HQK 62 HIF PH inhibitors 62 Phase 2a trial 62 dose limiting toxicities 62 antitumor effects 62 INSPIRE Trial Phase III 62 tolerability profile 62 Panzem R NCD 62 Darinaparsin 62 PS# [001] 62 prucalopride 62 CYT# 62 imetelstat 62 delafloxacin 62 antitumour activity 62 pharmacokinetic properties 62 Phase 1b clinical 62 double blinded placebo 62 subcutaneously administered 62 pain palliation 62 Sym# 62 optimal dosing 62 placebo controlled clinical 62 Phase 1a clinical 62 receptor tyrosine kinase inhibitor 62 Blinatumomab 62 CLORETAZINE TM VNP#M 62 huC# DM4 62 Androxal TM 62 depsipeptide 61 phase IIb clinical 61 GLPG# 61 sunitinib Sutent ® 61 investigational oral 61 pharmacokinetic interactions 61 Phase Ib II 61 IMC A# 61 active comparator 61 AAG geldanamycin analog 61 TACI Ig 61 Archexin 61 dose regimens 61 ELACYT 61 GAMMAGARD 61 dose escalation clinical 61 controlled multicenter Phase 61 cytoprotective 61 posaconazole 61 pertuzumab 61 orally dosed 61 Phase #/#a 61 HuMax EGFr 61 Panzem NCD 61 Phase IIb randomized 61 enzastaurin 61 randomized multicenter 61 metaglidasen 61 dasatinib Sprycel ® 61 Multimeric 61 administered subcutaneously 61 Apoptone 61 DermaVir Patch 61 huN# DM1 61 pharmacodynamic parameters 61 CIMZIA TM certolizumab pegol 61 Phase IIa clinical 61 ORMD 61 dosing regimens 61 NS5B polymerase 61 BAL# [002] 61 Omacetaxine mepesuccinate 61 nucleotide analog 61 DLTs 61 peripheral blood mononuclear 61 Pharmacokinetic studies 61 favorable pharmacokinetic 61 dose cohorts 61 pharmacodynamic endpoints 61 antitumor effect 61 CYP#A# CYP#D# 61 CCR5 mAb 61 relapsed MCL 61 crizotinib PF # 61 Onconase 61 PKC# 61 tanespimycin 61 Trofex 61 Cannabinor 61 label dose escalation 61 Phase Ib 61 Imprime PGG 61 demonstrated antitumor activity 61 vivo efficacy 61 cilengitide 61 HCV NS5B polymerase 61 vinca alkaloid 61 HSP# inhibitor 61 IMiDs ® 61 Hematologic toxicity 61 Phase IIb III 61 Phase 1a 61 HGS ETR1 mapatumumab 61 lorvotuzumab mertansine 61 TOLAMBA 61 confirmatory clinical 61 receptor inhibitor 61 trastuzumab emtansine T DM1 61 Hsp# Inhibitor 61 CDK inhibitor 61 Phase IIIb clinical 61 Thiovir 61 AKT inhibitor 61 unique alkylating agent 61 antidepressant efficacy 61 hemagglutination inhibition HAI 61 phase 2a 61 kinase inhibition 61 CA9 SCAN 61 efficacy 61 CYT# potent vascular disrupting 61 radezolid 61 JAK2 inhibitor 61 HCV protease 61 CA4P 61 prospectively defined 60 phase IIa 60 mTOR inhibitors 60 R#/MEM # 60 tumorigenicity 60 EXPLORE Xa 60 Aplidin R 60 talabostat 60 radiolabeled 60 dosage regimens 60 Phase 1b 60 genotoxicity 60 novel chimeric natriuretic 60 dose pharmacokinetic 60 non nucleoside 60 XL# XL# XL# XL# 60 subcutaneous PRO 60 STRIDE PD 60 randomized discontinuation trial 60 topoisomerase II inhibitor 60 XmAb# 60 CTAP# Capsules 60 urocortin 2 60 Phase 2b study 60 retaspimycin 60 non nucleoside inhibitor 60 class mGluR5 inhibitor 60 Pharmacodynamic 60 Phase IIa trial 60 TMC# C# 60 dose escalation phase 60 Rigel R# 60 Primary endpoints 60 multicenter randomized 60 dose cohort 60 KRN# 60 Triolex 60 cobiprostone 60 edoxaban 60 pathophysiological effects 60 ToGA 60 Omacetaxine 60 lomitapide 60 thymalfasin 60 ALB # 60 erythropoietic 60 EGFR HER2 60 intracellular uptake 60 PEGylated interferon beta 1a 60 ISIS # 60 tolerability profiles 60 Randomized Double blind 60 Annamycin 60 randomized Phase 2b 60 ascending dose study 60 ZACTIMA 60 blind randomized placebo 60 HMG CoA reductase inhibitors 60 neuroprotective properties 60 Aflibercept 60 vitro cytotoxicity 60 Darusentan 60 defensin mimetic antibiotic 60 hemostatic efficacy 60 treatment naive genotype 60 HGS ETR1 60 elotuzumab 60 Symadex 60 placebo controlled Phase 60 Traficet EN 60 prospective randomized multicenter 60 controlled multicenter 60 intravenously administered 60 Ophena TM 60 effector function 60 IMiDs R 60 sunitinib malate 60 florbetaben 60 samalizumab 60 Aclidinium 60 HGS# 60 highly selective inhibitor 60 metastatic HRPC 60 MEK inhibitor RDEA# 59 endothelin antagonists 59 retapamulin 59 trial evaluating PRX# 59 hematological parameters 59 By JENNIFER LEARN 59 Preclinical studies suggest 59 FOLOTYN ® 59 2 methoxyestradiol 59 Denufosol 59 immune modulating 59 PI3K/Akt pathway inhibitor 59 GFT# 59 Oral NKTR 59 GOUT 59 TransVax tm 59 CEQ# 59 budesonide foam 59 Phase 1b clinical trials 59 CIMZIA ™ 59 multiple ascending dose 59 refractory CLL 59 protein kinase inhibitor 59 Initiate Phase 59 weekly subcutaneous injections 59 phase Ib clinical 59 masitinib 59 eniluracil 59 REMINYL ® 59 CTA# Injection 59 5 Fluorouracil 59 Pharmacokinetic parameters 59 liposomal doxorubicin 59 AEGR 59 secretory phospholipase A2 sPLA2 59 milatuzumab 59 hypoxia activated prodrug 59 sorafenib Nexavar 59 #mg BID [003] 59 Initiated Phase 59 hENT1 59 MetMAb 59 RLY# 59 dacetuzumab 59 Exelixis compounds 59 longitudinal observational study 59 Phase 2b randomized 59 CYC# 59 abacavir lamivudine 59 melphalan prednisone 59 CaPre TM 59 mGluR5 NAM 59 ZD# [001] 59 Aztreonam lysine 59 CRLX# 59 RGB # 59 Immunomodulatory 59 cyclophilin inhibitor 59 Zalypsis 59 CCX# 59 BMS# 59 obatoclax 59 small molecule chemotherapeutic 59 dexamethasone Decadron 59 Seliciclib 59 estramustine 59 ZOLINZA 59 Annexin V 59 selective antagonist 59 potently inhibited 59 Sapacitabine 59 Val HeFT 59 Lp PLA 2 59 Alpharadin 59 dyskinesia PD LID 59 Vidofludimus 59 mg TID 59 MEND CABG II 59 XOMA 3AB 59 CD# monoclonal antibody 59 Novolimus 59 myeloproliferative disorders 59 bendamustine 59 RG# [001] 59 alkylating agent 59 BAY #-# 59 intravesical 59 heavily pretreated 59 blinded randomized 59 reversible inhibitor 59 #beta estradiol 59 Safinamide 59 pharmacokinetic studies 59 Akt activation 59 MGN# 59 tubulin inhibitor 59 Kinesin Spindle Protein KSP 59 achieved statistical significance 59 plasma lipoprotein 59 Phase III multicenter 59 antifibrotic 59 AERAS-#/Crucell Ad# 59 prospective multicentre 59 XP# Transported Prodrug 59 sorafenib tablets 59 Aplidin 59 MEND CABG 59 PEG PAL 59 Zoraxel 59 IMA# 59 romidepsin 59 radiolabeled TM# 59 FOLFOX6 chemotherapy regimen 59 sitaxsentan 59 novel histone deacetylase 59 serum leptin 59 dexpramipexole 59 Phase III randomized 59 Phase #/#a clinical 59 NO# [002] 59 afatinib 59 Phase 2a clinical 59 nonrandomized 59 dosed orally 59 MTP inhibitor 59 vitro experiments 59 potent antiviral 59 xenograft models 59 cathepsin K inhibitor 59 Elotuzumab 59 coadministration 59 subcutaneous doses 59 therapeutically relevant 59 peptide fragment 59 antineoplastic 59 TLK# 59 HIF PHI 59 Antiviral Activity 59 PSMA ADC 59 5 FU leucovorin 59 plasma kallikrein 59 torezolid 59 platelet inhibitor 59 APTIVUS r 59 VA# [002] 59 PI3K inhibitor 59 BoNTA 59 Trandolapril 59 immune modulator 59 EZN 59 Deforolimus 59 MEK inhibitor 59 multicenter randomized controlled 58 Personalized Immunotherapy 58 severe hypersensitivity reactions 58 Golimumab 58 KSP inhibitor 58 PDE4 inhibitor 58 Bezielle 58 multicenter placebo controlled 58 CB2 selective receptor agonist 58 PRIMO CABG 58 blinded placebo controlled 58 mycophenolate mofetil 58 Cloretazine ® 58 plus prednisone prednisolone 58 cannabinor 58 ocular formulation 58 Virulizin ® 58 kilogram mg kg 58 Tarvacin TM 58 humanized therapeutic 58 gemcitabine Gemzar ® 58 rHuPH# 58 multicenter Phase 58 APOPTONE 58 vapreotide acetate 58 antitumor 58 apremilast 58 IRX 2 58 non nucleoside HCV 58 RE LY ® 58 Kinoid 58 refractory chronic lymphocytic 58 aflibercept VEGF Trap 58 R baclofen 58 plasma lipid 58 K ras mutations 58 seliciclib 58 elacytarabine 58 landmark ATHENA 58 Posiphen 58 intravenous dosing 58 darunavir ritonavir 58 CCR5 antagonist 58 pharmacokinetic equivalence 58 papillary renal cell carcinoma 58 caspofungin 58 Sudhir Agrawal D.Phil 58 selective androgen receptor modulator 58 lintuzumab SGN 58 IFN α 58 refractory prostate cancer 58 Telik logo TELINTRA 58 latrepirdine 58 elastase 58 dopamine D2 58 interferon gamma 1b 58 #mg/m# [002] 58 Amphinex ® 58 BNC# 58 intermittent dosing 58 refractory NSCLC 58 immunomodulator 58 Parkinson disease levodopa induced 58 vicriviroc 58 Spiegelmer ® 58 plus Copegus R 58 dasatinib Sprycel 58 bovine thrombin 58 aplindore 58 GRN#L 58 oral JAK1 58 multicenter randomized clinical 58 vascular disrupting agent 58 EMPHASIS HF trial 58 Valortim ® 58 prospective randomized placebo 58 Linagliptin 58 docetaxel chemotherapy 58 potent neuroprotective 58 Forodesine HCl 58 ataluren 58 Anidulafungin 58 PEG Interferon lambda 58 placebo controlled 58 dosing cohort 58 Oral Fingolimod 58 antiangiogenic activity 58 eculizumab 58 hyperphenylalaninemia HPA due 58 Vidaza ® 58 teplizumab 58 CYP#C# genotype 58 radiation dosimetry 58 vorinostat 58 immunohistochemical 58 GRNVAC1 58 EOquin TM 58 Luteinizing Hormone Releasing Hormone 58 nucleoside analog 58 placebo controlled Phase III 58 APTIVUS 58 D aspartate NMDA receptor 58 REG2 58 IMGN# 58 FUSILEV enhances 58 novel anticancer 58 motesanib 58 randomized controlled Phase 58 cetuximab Erbitux R 58 rALLy clinical trial 58 DU #b 58 LAB CGRP 58 TRV# [001] 58 alfa 2a 58 Elvitegravir 58 GSK# [002] 58 Cloretazine R 58 genotoxic 58 Tolerability 58 superficial bladder cancer 58 assessing T DM1 58 Cloretazine R VNP#M 58 selective inhibition 58 Kinase Inhibitor 58 multicenter randomized double 58 GSK# [001] 58 tasimelteon 58 gemcitabine cisplatin 58 HIV coinfected 58 SAR# [004] 58 GRNCM1 58 mg kg dose 58 adecatumumab 58 OncoVEX GM CSF 58 Zenvia ™ 58 RAS MAPK pathway 58 randomized controlled clinical 58 highly immunogenic 58 liposomal amphotericin B 58 relapsed myeloma 58 forodesine 58 prasterone 58 ACTEMRA TM 58 INCB# [001] 58 mitogen activated ERK kinase 58 MAP# 58 placebo controlled multicenter 58 Prospective Randomized 58 tigecycline 58 tumor xenograft models 58 LibiGel ® 58 secondary efficacy endpoints 58 prospective observational 58 NOXAFIL Oral Suspension 58 rifalazil 58 Chemophase 58 Dual Opioid 58 includes TOLAMBA TM 58 ALN HPN 58 mecamylamine 58 randomized placebo controlled 58 CTA# 58 bevacizumab Avastin R 58 serum antibody 58 anti arrhythmic 58 isatoribine 58 NATRECOR ® 58 SUTENT ® 58 Phase #b/#a 58 TNFalpha 58 prospectively randomized 58 opioid naive 58 treatment naïve genotype 58 Methylnaltrexone 58 anti fibrotic 58 Xanafide 58 Fx #A 58 Medidur TM FA 58 antiresorptive 58 Pimavanserin 58 JVRS 58 HCV replicon 58 prokinetic agent 58 intravenous belinostat 58 PRIMO CABG2 58 midstage trials 58 cisplatin gemcitabine 58 doxorubicin cyclophosphamide 58 octreotide acetate 58 Lisofylline LSF 58 epoetin alpha 58 NGX# 58 phase III ACCLAIM 58 desvenlafaxine succinate 58 multi kinase inhibitor 58 multicenter phase 58 ARIKACE 58 sorafenib Nexavar ® 58 investigational monoclonal antibody 58 phase IIb trial 58 p# inhibitor 58 bicifadine 58 virologic 58 Triapine R 58 avosentan 58 flavopiridol 58 XL# XL# XL# 58 cMET 57 phase IIb 57 docetaxel Taxotere ® 57 PF # [001] 57 potent triglyceride lowering 57 optimal dosing regimens 57 VNP#M 57 randomized blinded 57 pegnivacogin 57 Prostate Lung Colorectal 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 YONDELIS 57 tumor hypoxia 57 IMPACT DCM 57 partial agonist 57 antiproliferative effects 57 Phase 2b clinical trials 57 antitumoral 57 atacicept 57 polymerase inhibitor 57 AIR CF1 57 FEMALES SHOULD BE ADVISED 57 potent inhibitor 57 TriRima 57 systemic RNAi therapeutic 57 LEXIVA r 57 eltrombopag 57 blind placebo controlled 57 selective orally bioavailable 57 placebo controlled clinical trials 57 CRMD# 57 potent antitumor activity 57 TLR8 agonist 57 AP# [003] 57 blind multicenter 57 Doxil ® 57 glufosfamide 57 AVOREN 57 angiotensin analog 57 intravenous bolus 57 Nanobody ® 57 noninferiority 57 Isolagen Therapy 57 HER2 positive metastatic breast 57 Romidepsin 57 5 HT2A inverse 57 pharmacokinetic pharmacodynamic PK PD 57 Randomized Phase 57 generation Hsp# inhibitor 57 non constipating irritable 57 potent anticancer 57 Bendavia 57 pharmacodynamic PK PD 57 histone deacetylase HDAC inhibitor 57 Ophena 57 vivo toxicology 57 clevidipine 57 IDX# 57 HOPE TOO 57 serum lipid 57 CIMZIA TM 57 Sphingomab 57 BFPET 57 chlamydial 57 splice variants 57 brivanib 57 THR beta agonist 57 mcg dose 57 urinary N telopeptide 57 RE SURGE 57 Panzem R 57 somatostatin analog 57 SYNTAX trial 57 mouse xenograft models 57 INCB# [002] 57 ONTARGET 57 HER2 expression 57 GLP toxicology studies 57 MIRCERA 57 CINQUIL 57 DB# [003] 57 docetaxel Taxotere R 57 Zybrestat 57 ponatinib 57 direct thrombin inhibitors 57 inhibitory effects 57 neoadjuvant 57 blind randomized controlled 57 mocetinostat MGCD# 57 nonclinical studies 57 relapsed refractory multiple myeloma 57 Pemetrexed 57 topically administered 57 targeted radiotherapeutic 57 multicenter prospective 57 bevacizumab Avastin ® 57 genotypic resistance 57 tumor subtypes 57 Belerofon 57 multicenter multinational 57 pan histone deacetylase 57 viral tropism 57 MET amplification 57 optimal dosing regimen 57 plus prednisone 57 Randomized controlled 57 eprotirome 57 CALGB # [002] 57 thrombin inhibiting aptamer 57 Hedgehog inhibitor 57 tezampanel 57 lixisenatide 57 selectively inhibits 57 MORAb 57 recurrent glioblastoma multiforme 57 HCV RESPOND 2 57 cynomolgus monkeys 57 histamine dihydrochloride 57 p# biomarker 57 IL# PE#QQR 57 prognostic significance 57 mg qd 57 replicon 57 pafuramidine 57 vitro antiviral 57 Prostate AdenoCarcinoma Treatment 57 immune modulatory 57 resolvin 57 evaluating Actimmune 57 MoxDuo ® IR 57 visilizumab 57 Phase #b/#a trial 57 imatinib resistant 57 muscarinic 57 pegylated liposomal doxorubicin 57 observer blinded randomized 57 LymphoStat B belimumab 57 Ribavirin causes 57 Obatoclax 57 investigational pan BCR 57 mg kg BID 57 CTCE 57 torezolid phosphate 57 LibiGel Phase III 57 Sorafenib HCC Assessment 57 Hsp# inhibitor 57 ADVANCE PD 57 tramiprosate Alzhemed TM 57 cardioprotective effects 57 CardioPET 57 pramlintide metreleptin combination 57 imatinib therapy 57 APPRAISE 57 Degarelix 57 HDAC Inhibitor 57 teduglutide 57 INCB# [003] 57 selective estrogen receptor modulator 57 aflibercept 57 ISTODAX 57 lactate dehydrogenase LDH 57 trabedersen 57 REG1 57 OMP #R# 57 Tanespimycin 57 thalidomide Thalomid 57 kinase inhibitor 57 randomized controlled clinical trials 57 imetelstat GRN#L 57 Telintra 57 insulin sensitizing 57 mg/m2 cohort 57 chemopreventive agent 57 serum cortisol 57 Anticalins 57 BRIM3 57 SRT# [003] 57 proteasome inhibitor 57 CORT # 57 Lacosamide 57 Alzhemed TM 57 Valortim R 57 trastuzumab Herceptin ® 57 Preclinical studies 57 target enzyme thymidylate 57 Vidaza azacitidine 57 thromboembolic complications 57 HCV SPRINT 57 Carotid Revascularization Endarterectomy vs. 57 ExTRACT TIMI 57 lanthanum carbonate 57 R# #mg BID 57 number NCT# ClinicalTrials.gov 57 bronchodilatory 57 azilsartan medoxomil 57 LY# [003] 57 mg QD 57 Phase 2b trial 57 cardiac repolarization 57 oestrogenic 57 LymphoStat B TM 57 placebo controlled studies 57 pro apoptotic 57 oral ridaforolimus 57 myopathy rhabdomyolysis 57 vascular disrupting agents 57 serum concentrations 57 TELCYTA 57 plasma renin activity 57 epigenetic therapies 57 LHRH receptor positive 57 Interferon alpha 57 GSK # 57 Phase IIIb 57 metastatic neuroendocrine tumors 57 XL# anticancer compounds 57 bepotastine besilate nasal spray 57 AVADO 57 LT NS# 57 Taxotere chemotherapy 57 Octreolin 57 IMiDs ® compound 57 RE LY trial 57 serum antibodies 57 Factor VIIa 57 capecitabine Xeloda R 57 double blind placebo 57 randomized controlled multicenter 57 Genasense ® oblimersen 57 lucinactant 57 ruxolitinib 57 QD dosing 57 Iloperidone 57 Azixa 57 OXi# 57 OMS# 57 PIX# [002] 57 Tasigna prolongs 57 Anturol TM 57 PNP inhibitor 57 IL #p# 57 registrational trial 57 5 HT2A receptor 57 elvitegravir 57 GAP #B# 56 Tezampanel 56 atazanavir ritonavir 56 PDE# inhibitors 56 antitumor efficacy 56 Phase IIIb study 56 trastuzumab Herceptin R 56 LCP Tacro 56 selective agonist 56 registrational